This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Schoor, J Articles by Pauwels, R. Search for Related Content PubMed PubMed Citation Articles by Van Schoor, J Articles by Pauwels, R.

Clinical Trial

The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics

Inhalation of neurokinin (NK) A causes bronchoconstriction in patients with asthma. The NKA-induced bronchoconstriction in isolated human airways is mediated via the NK2 receptor and inhibited by SR 48968, a potent and specific nonpeptide tachykinin NK2 receptor antagonist. In the present study, the effect of orally administered SR 48968 on NKA-induced bronchoconstriction was examined in 12 mild asthmatics. On the screening day and during the study periods, increasing concentrations of NKA (3.3 x 10(-9) to 1.0 x 10(-6) mol x mL(-1)) were inhaled, until the forced expiratory volume in one second (FEV1) and specific airway conductance (sGaw) decreased by at least 20 and 50%, respectively. During the study periods, 100 mg SR 48968 or matched placebo was ingested in a double-blind, randomized, crossover fashion and NKA provocation was performed at 1.5 and 24 h after dosing. At 1.5 h, the mean (SEM) log10 provocative concentration of NKA causing a 20% fall in FEV1 (PC20 FEV1) was -6.25 (0.20) after SR 48968 and -6.75 (0.17) after placebo (p=0.05); the mean log10 provocative concentration of NKA causing a 35% fall in sGaw (PC35 sGaw) was -7.02 (0.28) after SR 48968 and -7.64 (0.19) after placebo (p=0.05). At 24 h, the mean log10 PC20 FEV1 was -6.21 (0.17) after SR 48968 and -6.65 (0.11) after placebo (p=0.05); the mean log10 PC35 sGaw was -6.85 (0.23) after SR 48968 and -7.17 (0.15) after placebo (nonsignificant). As PC20 FEV1 and/or PC35 sGaw were not reached in up to 4 patients per SR 48968 group, the differences between SR 48968 and placebo were underestimated. In conclusion, oral treatment with 100 mg SR 48968 caused a significant inhibition of neurokinin A-induced bronchoconstriction in asthmatics. This finding constitutes the first evidence of inhibition of sensory neuropeptide-induced bronchoconstriction by a selective tachykinin receptor antagonist in humans.

This article has been cited by other articles:

				V. Schelfhout, V. Van De Velde, C. Maggi, R. Pauwels, and G. Joos The effect of the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in asthmatics Therapeutic Advances in Respiratory Disease, October 1, 2009; 3(5): 219 - 226. [Abstract] [PDF]

				J. D. Boot, S. de Haas, S. Tarasevych, C. Roy, L. Wang, D. Amin, J. Cohen, P. J. Sterk, B. Miller, A. Paccaly, et al. Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 450 - 457. [Abstract] [Full Text] [PDF]

				P. E. Losco, M. W. Leach, D. Sinha, P. Davis, T. J. Schmahai, A. Nomier, T. Kakkar, L. Reyderman, and M. E. Lynch Administration of an Antagonist of Neurokinin Receptors 1, 2, and 3 Results in Reproductive Tract Changes in Beagle Dogs, but Not Rats Toxicol Pathol, February 1, 2007; 35(2): 310 - 322. [Abstract] [Full Text] [PDF]

				P.J. Franklin, S.W. Turner, R.C. Mutch, and S.M. Stick Comparison of single-breath and tidal breathing exhaled nitric oxide levels in infants Eur. Respir. J., March 1, 2004; 23(3): 369 - 372. [Abstract] [Full Text] [PDF]

				G.F. Joos, W. Vincken, R. Louis, V.J. Schelfhout, J.H. Wang, M.J. Shaw, G.D. Cioppa, and R.A. Pauwels Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Eur. Respir. J., January 1, 2004; 23(1): 76 - 81. [Abstract] [Full Text] [PDF]

				G.F. Joos and B. O'Connor Indirect airway challenges Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068. [Abstract] [Full Text] [PDF]

				J. Van Schoor, G.F. Joos, and R.A. Pauwels Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma Eur. Respir. J., June 1, 2002; 19(6): 997 - 1002. [Abstract] [Full Text] [PDF]

				E. L. J. Van Rensen, P. S. Hiemstra, K. F. Rabe, and P. J. Sterk Assessment of Microvascular Leakage via Sputum Induction: The Role of Substance P and Neurokinin A in Patients with Asthma Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1275 - 1279. [Abstract] [Full Text] [PDF]

				S. AMADESI, J. MOREAU, M. TOGNETTO, J. SPRINGER, M. TREVISANI, E. NALINE, C. ADVENIER, A. FISHER, D. VINCI, C. MAPP, et al. NK1 Receptor Stimulation Causes Contraction and Inositol Phosphate Increase in Medium-size Human Isolated Bronchi Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1206 - 1211. [Abstract] [Full Text]